U.S. Markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
58.74-0.39 (-0.66%)
At close: 4:00PM EDT
Sign in to post a message.
  • R
    $INO conversation
    Merck, AstraZeneca: Positive Results From the Phase 3 PROpel Trial

    Merck, AstraZeneca: Independent Data Monitoring Committee Concluded That the Trial Met the Primary Endpoint
    $MRK $AZN
  • R
    Real Immunotrader 10
    $AZN Nice Move in A Bloody Market / Worth $9B More today than Yesterday
    58.50+2.94 (+5.29%) Market Cap 181.454B. ADDED $9B In Market Cap, Due to Interim Phase 3 Data / $SLS is on DECK back to Back Grand slams incoming +1,000% to 5,000% AML Phase 3 Fda a virtual Lock DD
  • K
    Alexion purchase, positive cancer news almost weekly, Farxiga growing with CKD indication, shortly a new reliever inhaler that could be a game changer for asthma sufferers in USA…. See a stock price approaching $70 by year end.
  • B
    Barnacle Barney
    I guess curing cancer isn't what it used to be ? Not even a new 52 week high.
  • M
    AZN just made another mistake by investing in saRNA. Too late. VaxEquity does not own this technology. It is based on highly deadly virus, which causes encephalitis. Several large and small companies tried to use this vector for vaccines for over 30 years, but so far unsuccessful. Interestingly Imperial College abruptly stopped clinical trials for saRNA COVID vaccine.
  • R
    Well personally I feel, those who would allow the market dynamism determine when to trade or not are either new in crypto currency world in general or probably just naive, crypto currencies have seen far worse times and even better times than this, enlightened traders continue to make good use of the dip even acquiring more equities towards trading sessions, 6 months back I started trading, though i knew just the basics of trading, I've seen a lot of money been made from crypto trading just within weeks, i wasn't able to capture the secret to understanding the use of signals till I got connected to trading expert Mr Randy Griffin. Under his guide I've been able to understand the market structure and how best to use signals for amazing returns, plus his trading classes has been so educative, Randy Griffin makes you learn while earning massively alongside, Jerry Jones can be contacted for crypto inclined concerns Telegram@Griffinsignals.
  • r
    lol where my post at?
  • D
    $BDTX conversation
    $bdtx unanimous strong buys with price target $46.25 at https://www.nasdaq.com/market-activity/stocks/bdtx/analyst-research and https://www.tipranks.com/stocks/bdtx/forecast $rvmd $goss $azn $pfe
  • k
    Azn receives Japan’s approval for new kidney drug treatment todzy
  • A
    AstraZeneca, has great prospects ahead. An advanced drugs pipeline second to none, strong position in the fight against cancer, boosted by the bedding down of the Alexion acquisition, means double digit growth ahead for the rest of this decade, although the share price is not exactly cheap.
  • C
    AZN pays two unequal half dividend. We just had the small one of 44c. The big one comes in February and is 94c.
    They bought Alexion to increase the dividend. That is what it will take to get the pps up. If it were to pay $1 each time we might see $60 again but $1.50 x2 might get us to $70
  • h
    They had some interesting insights about AZN on (http://Fairstox.com). Definitely made me think twice about the company.
  • A
    Management has to go!
  • L
    What about the dividend? Thought they were supposed to announce it in this report.
  • A
    will be at $72.00 by the end of August
  • E
    E A
    SVB Leerlink maintains Outperform on AZN and raises their price target from $63 to $69…

  • S
    AZN cocktail 70% effective should get this thing moving. Tried posting link to article but post got deleted
  • D
    Dennis Paul
    Getting closer to buy territory, x dividend date Aug. 12 th.
  • p
    62+ by Friday. It has a positive path to succeed.
  • A
    Pieris Pharmaceuticals, Inc.
    Five active collaborations leaves many potential milestones to be achieved' candidate selection is potential in all programs, initial efficacy from Phase 2a for asthma with $AZN, and many more.

    Numbers in August showing a boost to the cash could also trigger some analyst re-ratings.

    The pace of execution has accelerated here.